Medtronic
 
 

Heart Failure

Concerto™ CRT-D Device1

with Conexus™ Wireless Telemetry

Concerto CRT-D Device
[+] Click to enlarge

Orchestrated Care
The first complete system to assist in managing heart disease*

Adaptive Therapies
Essential Insight
Wireless Connectivity

What if you could provide proactive care before the onset of heart failure problems?

The Concerto cardiac resynchronization therapy device and defibrillator (CRT-D) with Conexus Wireless Telemetry signals a new era in managing heart failure.

Wireless Connectivity

Potentially more efficient case management
In addition to innovative therapies and advanced diagnostics, Concerto CRT-D provides:

*Concerto™ CRT-D with Conexus™ Wireless Telemetry, Medtronic CareLink programmer and Medtronic CareLink Network, Model 27901 Conexus Activator.

Concerto CRT-D

  • 35 J delivered
  • 8 seconds BOS**
  • 9.9 seconds RRT***
  • 5.4 years 2
  • 38 cc, 68 g

**Beginning of Service
*** Recommended Replacement Time

Adaptive Therapies to monitor and ensure therapy when needed

Left Ventricular Capture Management (LVCM)

Advances to Ensure Cardiac Resynchronization Therapy

Fewer Shocks with ATP During Charging3,4

ATP During Charging

ATP During Charging

View Animation

This animation requires the latest version of the Macromedia Flash Player. Get player

Essential Insight for more informed disease management

New Era of Telemedicine
- know which patients need a follow-up call and why.

Medtronic CareAlert

Care Alert Notifications
with Conexus Wireless Telemetry

View Animation

This animation requires the latest version of the Macromedia Flash Player. Get player

Physician-selected Medtronic CareAlert Notifications provide your staff with a "management by exception" system based on objective data to potentially achieve better, more efficient case management.

OptiVol™ Fluid Status Monitoring

Making Fluid Visible

View Animation

This animation requires the latest version of the Macromedia Flash Player. Get player

OptiVol Fluid Status Monitoring Provides Unprecendented Insight into Patients' Clinical Status.

  • Lung congestion is a major complication in heart failure patients. 6-7
  • OptiVol allows you to continually track your patients’ fluid status using intrathoracic impedance.
  • Provides trending data to adjust medical treatment for patients at risk of acute decompensated heart failure.
  • Available on Medtronic CareLink Network enabling you to check on your patient’s fluid status from their home.

Cardiac Compass® Trends and Heart Failure Management Reports

Heart Failure Management Reports
Heart Failure
Management Report
[+] Enlarge View

The Cardiac Compass Trends Report provides 14 months of trended information on OptiVol Fluid Status Monitoring and other key parameters such as:

  • Total daily AT/AF time
  • Heart rate variability
  • Average ventricular rate (day & night)
  • Patient activity
  • Percent pacing

Other Advanced Cardiac Resynchronization + ICD Therapies and Mechanical Specifications

References
  1. Medtronic Concerto CRT-D implant and reference manuals.
  2. DDD, 15% atrial pacing at 60 min -1 average rate, the remaining percentage atrial tracking at 70 min -1 average rate, 100% biventricular pacing, 2.5 V/0.4 (A and RV), 3 V/0.4 (LV), 500 ohms equivalent pacing loads, pre-arrhythmia EGM storage on, 2 full energy charges per year. Programming pre-arrhythmia EGM to “off” increases longevity by 18% or 2.1 months per year.
  3. Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation. August 14, 2001;104(7):796-801.
  4. Wathen MS, DeGroot PJ, Sweeney MO, et. al., for the PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators. Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) Trial results. Circulation. 2004;110:2591-2596.
  5. Ahmad M, Bloomstein L, Roehlke M, Bernstein AD, Parsonnet V. Patients'attitudes toward implanted defibrillator shocks. PACE. June 2000;23(6):934-938.
  6. Gheorghiade M, Gattis W, O'Connor C, et al. Effects of Tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA. 2004;291:1963-1971.
  7. 7 Gattis W, O'Connor C, Gallup D, et al. Predischarge initiation of Carvedilol in patients hospitalized for decompensated heart failure. J Am Coll Cardiol. 2004;43:1534-1541.

 

 

Additional Information